Free tool
FAERS Monitor: Vascepa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202057 or its brand name (Vascepa, Icosapent Ethyl). Reports on generic versions are filed under their own applications.
Reports
8,228
Serious
2,986
36% of reports
Hospitalization
1,368
Death reported
422
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product odour abnormal1,055
- product physical issue915
- off label use675
- poor quality product administered668
- diarrhoea525
- nausea504
- product taste abnormal451
- drug ineffective450
- arthralgia399
- fatigue350
- blood triglycerides increased305
- eructation281
- prescribed underdose257
- dizziness242
- headache240
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 75 |
| 2014 | 102 |
| 2015 | 208 |
| 2016 | 207 |
| 2017 | 350 |
| 2018 | 391 |
| 2019 | 659 |
| 2020 | 939 |
| 2021 | 1,176 |
| 2022 | 801 |
| 2023 | 772 |
| 2024 | 759 |
| 2025 | 952 |
| 2026 | 831 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,931 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product odour abnormalSignal | 1,055 | 286.2 | 269.6 | 269,535 |
| poor quality product administeredSignal | 668 | 172.9 | 160.4 | 106,832 |
| product physical issueSignal | 915 | 121.4 | 114.0 | 104,291 |
| product taste abnormalSignal | 451 | 88.0 | 80.4 | 37,458 |
| blood triglycerides increasedSignal | 305 | 44.9 | 40.2 | 12,831 |
| eructationSignal | 281 | 37.7 | 33.5 | 9,854 |
| prescribed underdoseSignal | 257 | 33.3 | 29.5 | 7,936 |
| arthralgiaSignal | 399 | 2.5 | 2.2 | 349 |
| diarrhoeaSignal | 525 | 2.1 | 1.9 | 302 |
| off label use | 675 | 2.0 | 1.8 | 336 |
| nausea | 504 | 1.6 | 1.5 | 126 |
| dizziness | 242 | 1.2 | 1.1 | 11 |
| fatigue | 350 | 1.1 | 1.0 | 7 |
| headache | 240 | 1.0 | 0.9 | 0 |
| drug ineffective | 450 | 0.9 | 0.8 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.